Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists reply

被引：1
|
作者：
Walus-Miarka, Malgorzata [1 ]
Kapusta, Maria [2 ]
Miarka, Przemyslaw [3 ]
Trojak, Aleksandra [1 ]
Idzior-Walus, Barbara [1 ]
Malecki, Maciej T. [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Dept Metab Dis, Ul Kopernika 15, PL-31501 Krakow, Poland
[2] Jagiellonian Univ, Coll Med, Dept Biochem, Krakow, Poland
[3] Jagiellonian Univ, Coll Med, Dept Nephrol, Krakow, Poland
来源：
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ | 2019年 / 129卷 / 09期
关键词：
D O I：
10.20452/pamw.14999
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：649 / 650
页数：2
相关论文
共 50 条
  • [1] Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists
    Patoulias, Dimitrios
    Kalogirou, Maria-Styliani
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Doumas, Michael
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2019, 129 (09): : 648 - 649
  • [2] The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
    Tsiampali, Chara
    Papaioannidou, Paraskevi
    Goulas, Antonis
    Polyzos, Stergios A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (11) : 1063 - 1072
  • [3] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [4] Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
    Tran, Kelvin Lingjet
    Park, Young In
    Pandya, Shalin
    Muliyil, Navin John
    Jensen, Brandon David
    Huynh, Kovin
    Nguyen, Quang T.
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (04): : 178 - 187
  • [5] Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease-Current Background, Hopes, and Perspectives
    Cazac, Georgiana-Diana
    Lacatusu, Cristina-Mihaela
    Stefanescu, Gabriela
    Mihai, Catalina
    Grigorescu, Elena-Daniela
    Onofriescu, Alina
    Mihai, Bogdan-Mircea
    METABOLITES, 2023, 13 (05)
  • [6] Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
    Kuo, Chia-Chih
    Chuang, Min-Hsiang
    Li, Chun-Hsien
    Tsai, Ya-Wen
    Huang, Po-Yu
    Kuo, Hsing-Tao
    Lai, Chih-Cheng
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (07) : 1163 - 1174
  • [7] Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes
    Edwards, C. M. B.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (04) : 198 - 201
  • [8] Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease
    Tsiampali, Chara
    Vachliotis, Ilias D.
    Goulas, Antonis
    Polyzos, Stergios A.
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2024, 23 (04): : 611 - 619
  • [9] Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
    van Dalem, Judith
    Driessen, Johanna H. M.
    Burden, Andrea M.
    Stehouwer, Coen D. A.
    Klungel, Olaf H.
    de Vries, Frank
    Brouwers, Martijn C. G. J.
    HEPATOLOGY, 2021, 74 (05) : 2467 - 2477
  • [10] Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
    Lund, Asger
    Knop, Filip K.
    Vilsboll, Tina
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (05) : 407 - 414
12345